Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice.

[1]  R. Landewé,et al.  ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update , 2022, Annals of the Rheumatic Diseases.

[2]  R. Ramonda,et al.  Secukinumab Drug Survival in Psoriasis and Psoriatic Arthritis Patients: A 24-Month Real-Life Study , 2022, Dermatology.

[3]  A. Bergamini,et al.  Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study , 2022, Therapeutic advances in musculoskeletal disease.

[4]  M. Dougados,et al.  The ASAS-OMERACT core domain set for axial spondyloarthritis. , 2021, Seminars in arthritis and rheumatism.

[5]  H. Mann,et al.  Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries , 2021, Arthritis care & research.

[6]  V. Strand,et al.  Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long‐Term Results of Two Phase III Randomized Controlled Trials , 2020, Arthritis care & research.

[7]  G. Macfarlane,et al.  Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration , 2020, RMD open.

[8]  J. Primdahl,et al.  EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update , 2020, Annals of the Rheumatic Diseases.

[9]  Claudia Fabiani,et al.  Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis , 2020, Mediators of inflammation.

[10]  R. Sengupta,et al.  Real-world experience of secukinumab treatment for ankylosing spondylitis at the Royal National Hospital for Rheumatic Diseases, Bath , 2020, Clinical Rheumatology.

[11]  J. P. Pinto Tasende,et al.  Secukinumab as Biological Treatment for Psoriatic Arthritis in Real Clinical Practice. , 2019, Reumatologia clinica.

[12]  V. Strand,et al.  Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study. , 2019, Clinical and experimental rheumatology.

[13]  P. Tugwell,et al.  OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies , 2019, The Journal of Rheumatology.

[14]  V. Strand,et al.  Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study , 2018, Arthritis Research & Therapy.

[15]  D. M. van der Heijde,et al.  Health-related quality of life in patients with psoriatic and rheumatoid arthritis: data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls , 2018, Annals of the rheumatic diseases.

[16]  H. Marzo-Ortega,et al.  Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2 , 2017, RMD Open.

[17]  J. Sieper,et al.  Axial spondyloarthritis , 2017, The Lancet.

[18]  S. Gaffen,et al.  IL-17 Signaling: The Yin and the Yang. , 2017, Trends in immunology.

[19]  M. Dougados,et al.  2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis , 2017, Annals of the rheumatic diseases.

[20]  B. Shea,et al.  International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials , 2016, Annals of the rheumatic diseases.

[21]  M. Hiligsmann,et al.  Which aspects of health are most important for patients with spondyloarthritis? A Best Worst Scaling based on the ASAS Health Index. , 2016, Rheumatology.

[22]  V. Strand,et al.  Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1) , 2016, Annals of the rheumatic diseases.

[23]  M. D. de Wit,et al.  Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set , 2016, RMD Open.

[24]  M Cutolo,et al.  European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update , 2015, Annals of the rheumatic diseases.

[25]  I. Olivieri,et al.  Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. , 2015, Rheumatology.

[26]  E. Kilic,et al.  Relationship Between Psychiatric Status, Self-Reported Outcome Measures, and Clinical Parameters in Axial Spondyloarthritis , 2014, Medicine.

[27]  P. Tugwell,et al.  Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. , 2014, Journal of clinical epidemiology.

[28]  A. Loft,et al.  Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. , 2013, Arthritis and rheumatism.

[29]  A. Loft,et al.  Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry , 2012, Annals of the rheumatic diseases.

[30]  P. Tugwell,et al.  American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials , 2011, Annals of the rheumatic diseases.

[31]  W. Dixon,et al.  EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology , 2010, Annals of the rheumatic diseases.

[32]  M. Østergaard,et al.  Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry , 2010, Annals of the rheumatic diseases.

[33]  M. Dougados,et al.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection , 2009, Annals of the rheumatic diseases.

[34]  L. Coates,et al.  Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment , 2009, Annals of the rheumatic diseases.

[35]  Dafna Gladman,et al.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.

[36]  P. Geborek,et al.  The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. , 2006, Arthritis and rheumatism.

[37]  J J Anderson,et al.  Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. , 2001, Arthritis and rheumatism.

[38]  A. Cats,et al.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. , 1984, Arthritis and rheumatism.

[39]  D. Gladman,et al.  Psoriatic Arthritis. , 2017, The New England journal of medicine.